revealing a new class of oncology targets. These targets support the development of cellular therapies and personalized cancer vaccines designed to enhance cellular immune responses against solid and hematological malignancies. AilseBio works within the immuno-oncology and drug discovery fields to provide tools that expand the range of actionable cancer-specific antigens. The company currently is in creditors' voluntary liquidation but its platform and approach remain relevant to next-generation immunotherapy research and development.